Modulation of Tau Isoforms Imbalance Precludes Tau Pathology and Cognitive Decline in a Mouse Model of Tauopathy.

Cell Rep

Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Consejo Nacional de Investigaciones Científicas y Técnicas (INGEBI-CONICET), Buenos Aires, Argentina. Electronic address:

Published: April 2018

The microtubule-associated protein tau regulates myriad neuronal functions, such as microtubule dynamics, axonal transport and neurite outgrowth. Tauopathies are neurodegenerative disorders characterized by the abnormal metabolism of tau, which accumulates as insoluble neuronal deposits. The adult human brain contains equal amounts of tau isoforms with three (3R) or four (4R) repeats of microtubule-binding domains, derived from the alternative splicing of exon 10 (E10) in the tau transcript. Several tauopathies are associated with imbalances of tau isoforms, due to splicing deficits. Here, we used a trans-splicing strategy to shift the inclusion of E10 in a mouse model of tauopathy that produces abnormal excess of 3R tau. Modulating the 3R/4R ratio in the prefrontal cortex led to a significant reduction of pathological tau accumulation concomitant with improvement of neuronal firing and reduction of cognitive impairments. Our results suggest promising potential for the use of RNA reprogramming in human neurodegenerative diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.03.079DOI Listing

Publication Analysis

Top Keywords

tau isoforms
8
mouse model
8
model tauopathy
8
tau
7
modulation tau
4
isoforms imbalance
4
imbalance precludes
4
precludes tau
4
tau pathology
4
pathology cognitive
4

Similar Publications

A hallmark of Alzheimer disease (AD) and tauopathies, severe neurodegenerative diseases, is the progressive aggregation of Tau, also known as microtubule-associated Tau protein. Full-length Tau, also known as 2N4R, contains two N-terminal inserts that bind to tubulin. This facilitates the self-assembly of tubulin simultaneously enhancing stability of cell microtubules.

View Article and Find Full Text PDF

Neuronal CD59 isoforms IRIS-1 and IRIS-2 as regulators of neurotransmitter release with implications for Alzheimer's disease.

Alzheimers Res Ther

January 2025

Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, 214-28, Sweden.

We have previously demonstrated that the intracellular, non-GPI anchored CD59 isoforms IRIS-1 and IRIS-2 (Isoforms Rescuing Insulin Secretion 1 and 2) are necessary for insulin secretion from pancreatic β-cells. While investigating their expression across human tissues, we identified IRIS-1 and IRIS-2 mRNA in the human brain, though their protein expression and function remained unclear. This study shows the presence of both IRIS-1 and 2 proteins in the human brain, specifically in neurons and astrocytes.

View Article and Find Full Text PDF

Current Progress and Future Directions in Non-Alzheimer's Disease Tau PET Tracers.

ACS Chem Neurosci

January 2025

Research Center for Accelerator and Radioisotope Science, Tohoku University, Sendai, Miyagi 980-0845, Japan.

Alzheimer's disease (AD) and non-AD tauopathies are dominant public health issues driven by several factors, especially in the aging population. The discovery of first-generation radiotracers, including [F]FDDNP, [C]PBB3, [F]flortaucipir, and the [F]THK series, for the in vivo detection of tauopathies has marked a significant breakthrough in the fields of neuroscience and radiopharmaceuticals, creating a robust new category of labeled compounds: tau positron emission tomography (PET) tracers. Subsequently, other tau PET tracers with improved binding properties have been developed using various chemical scaffolds to target the three-repeat/four-repeat (3R/4R) tau folds in AD.

View Article and Find Full Text PDF

Plasma phospho-tau217 as a predictive biomarker for Alzheimer's disease in a large south American cohort.

Alzheimers Res Ther

January 2025

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, 10032, USA.

Article Synopsis
  • Blood-based biomarkers like p-tau217 are being studied for their effectiveness in diagnosing Alzheimer's disease (AD), but previous research has mainly focused on non-Hispanic White populations, leading to a knowledge gap across different ethnic backgrounds.
  • A new study involving Peruvians, including mestizos and indigenous groups, examined plasma p-tau217 in 525 individuals, revealing significant associations between the biomarker and AD, especially in those with the APOE-e4 allele, although it did not distinguish between healthy controls and mild cognitive impairment (MCI).
  • The results indicated that p-tau217 levels correlated well with cognitive performance and had an impressive classification performance (ROC-AUC of 82.82%), marking a significant contribution to understanding AD in diverse
View Article and Find Full Text PDF

Introduction: Type 2 diabetes increases the risk of Alzheimer's disease (AD) dementia. Insulin signaling dysfunction exacerbates tau protein phosphorylation, a hallmark of AD pathology. However, the comprehensive impact of diabetes on patterns of AD-related phosphoprotein in the human brain remains underexplored.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!